Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Phenmetrazine (compound)


PubChem
Name: Phenmetrazine
PubChem Compound ID: 10329865
Description: A sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to DEXTROAMPHETAMINE.
Molecular formula: C11H15NO
Molecular weight: 177.243 g/mol
DrugBank
Identification
Name: Phenmetrazine
Name (isomeric): DB00830
Drug Type: small molecule
Description: A sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to DEXTROAMPHETAMINE.
Synonyms:
Defenmetrazin; Fenmetrazina [INN-Spanish]; 2-Phenyl-3-Methylmorpholine; Fenmetrazin; Phenmetraline hydrochloride; USAF Ge-1; 3-Methyl-2-phenylmorpholine; Oxazimedrine; Dexphenmetrazine; Phenmetrazinum [INN-Latin]
Brand: Phenmetrazin, Preludin hydrochloride, Probese-P hydrochloride, Neo-zine, Preludin, Marsin, Bromadryl, Phenmetrazine hydrochloride, Psychamine A 66, Mefolin, Probese-P, Cafilon, Psychamine A 66 hydrochloride
Category: Sympathomimetics, Appetite Depressants, Central Nervous System Stimulants, Central Nervous System Agents
CAS number: 134-49-6
Pharmacology
Indication: Used as an anorectic in the treatment of obesity.
Pharmacology:
Phenmetrazine is a sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. Phenmetrazine was originally sold under the tradename Preludin as an anorectic. It has since been removed from the marke...
show more »
Mechanism of Action:
Phenmetrazine is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron leading to an increase in the release of these monoamines into the extraneuronal space. Dopamine integrates incoming sensory stimuli, initiates and controls fine movement (nigro-neostriatal pathway), controls emotional behavior (midbrain mesoli...
show more »
Absorption: Readily absorbed from the gastro-intestinal tract and buccal mucosa.
Biotransformation: Primarily hepatic (via CYP3A and CYP2D6). Resistant to metabolism by monoamine oxidase. Metabolism involves deamination to para-hydroxyamphetamine and phenylacetone; this latter compound is subsequently oxidize to benzoic acid and excreted as glucuronide or glycine (hippuric acid) conjugate. Smaller amounts of amphetamine are converted to norephedrine by oxidation.
Half Life: 16 to 31 hours
Toxicity: Adult monkeys have an LD50 of 15 to 20 mg/kg, whereas for young monkeys the LD50 is only 5 mg/kg. Symptoms of overdose include acute central nervous system stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension, and cardiovascular collapse. Whilst some patients show signs of toxicity at blood concentrations of 20 µg/L, chronic abusers of amphetamine have been known to have blood concentration of up to 3000 µg/L.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
MesoridazineDecreased anorexic effect, may increase psychotic symptoms
ChlorpromazineDecreased anorexic effect, may increase psychotic symptoms
FluphenazineDecreased anorexic effect, may increase psychotic symptoms
PromethazineDecreased anorexic effect, may increase pyschotic symptoms
ProchlorperazineDecreased anorexic effect, may increase pyschotic symptoms
show more »

Targets